Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17543545 | 1.00 | OPRD1 (0.31) | OPRD1OPRK1CXCR3GRM2GRIN2C | |
| SCHEMBL17543038 | 0.94 | GRM2 (0.31) | OPRD1OPRK1GRM2GRIN2CTHRB | |
| SCHEMBL28413584 | 0.94 | P2RX7 (0.33) | OPRD1OPRK1 | |
| SCHEMBL17543591 | 0.91 | THRB (0.32) | OPRD1OPRK1GRM2GRIN2CTHRB | |
| SCHEMBL17542856 | 0.91 | THRB (0.32) | OPRD1OPRK1GRM2GRIN2CTHRB | |
| SCHEMBL17542906 | 0.91 | THRB (0.32) | OPRD1OPRK1GRM2GRIN2CTHRB | |
| SCHEMBL17542909 | 0.91 | THRB (0.32) | OPRD1OPRK1GRM2GRIN2CTHRB | |
| SCHEMBL17543649 | 0.89 | THRB (0.32) | OPRD1OPRK1CXCR3THRB | |
| SCHEMBL17542918 | 0.89 | THRB (0.32) | OPRD1OPRK1CXCR3THRB | |
| SCHEMBL17543061 | 0.88 | GHSR (0.33) | OPRD1OPRK1CXCR3GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | OPRD1 2165/4885OPRK1 2535/4885CXCR3 1736/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | OPRD1 2165/4885OPRK1 2535/4885CXCR3 1736/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | OPRD1 2165/4885OPRK1 2535/4885CXCR3 1736/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | OPRD1 2165/4885OPRK1 2535/4885CXCR3 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.